SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-049463
Filing Date
2023-09-22
Accepted
2023-09-22 17:10:48
Documents
13
Period of Report
2023-09-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K omga-20230922.htm   iXBRL 8-K 59686
2 EX-10.1 omga-ex10_1.htm EX-10.1 75454
  Complete submission text file 0000950170-23-049463.txt   268632

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT omga-20230922.xsd EX-101.SCH 2479
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT omga-20230922_lab.xml EX-101.LAB 13904
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT omga-20230922_pre.xml EX-101.PRE 11435
7 EXTRACTED XBRL INSTANCE DOCUMENT omga-20230922_htm.xml XML 4885
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 231272420
SIC: 2836 Biological Products, (No Diagnostic Substances)